VERTEX PHARMACEUTICALS INC / MA Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $13.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, income tax penalties and interest expense for the quarter ending 2019-06-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, income tax penalties and interest expense for the quarter ending 2019-03-31 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, income tax penalties and interest expense for the quarter ending 2018-09-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, income tax penalties and interest expense for the quarter ending 2018-06-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, income tax penalties and interest expense for fiscal 2025 was $13.10M.
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, income tax penalties and interest expense for fiscal 2024 was -$41.50M, a 148.88% decline from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, income tax penalties and interest expense for fiscal 2023 was $84.90M, a 131.97% increase from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, income tax penalties and interest expense for fiscal 2022 was $36.60M.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 3 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 6 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 9 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $13.10M 10-K · filed 2026-02-13 | |||
| 2024-12-31 | -$41.50M 10-K · filed 2026-02-13 | |||
| 2023-12-31 | $84.90M 10-K · filed 2026-02-13 | |||
| 2022-12-31 | $36.60M 10-K · filed 2025-02-13 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-15 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-10 | |||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-01 | $0.00 10-Q · filed 2019-08-01 | ||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-01 | |||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | $0.00 derived: sum of 2 quarters · filed 2019-08-01 | $0.00 10-Q · filed 2018-10-25 | $0.00 derived: sum of 4 quarters · filed 2019-08-01 |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-01 | $0.00 10-Q · filed 2019-08-01 | $0.00 derived: sum of 3 quarters · filed 2019-08-01 | $0.00 derived: sum of 4 quarters · filed 2019-08-01 |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-01 | $0.00 derived: sum of 2 quarters · filed 2019-05-01 | $0.00 derived: sum of 3 quarters · filed 2019-05-01 | $0.00 derived: sum of 4 quarters · filed 2019-05-01 |
| 2017-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2018-10-25 | $0.00 derived: sum of 2 quarters · filed 2018-10-25 | $0.00 derived: sum of 3 quarters · filed 2018-10-25 | $0.00 10-Q · filed 2018-10-25 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30 | $0.00 derived: sum of 2 quarters · filed 2017-10-30 | $0.00 10-Q · filed 2017-10-30 | $0.00 derived: sum of 4 quarters · filed 2017-10-30 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $0.00 10-Q · filed 2017-07-28 | $0.00 derived: sum of 3 quarters · filed 2017-10-30 | $0.00 derived: sum of 4 quarters · filed 2017-10-30 |
| 2017-03-31 | $0.00 10-Q · filed 2017-04-28 | $0.00 derived: sum of 2 quarters · filed 2017-10-30 | $0.00 derived: sum of 3 quarters · filed 2017-10-30 | $0.00 derived: sum of 4 quarters · filed 2017-10-30 |
| 2016-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2017-10-30 | $0.00 derived: sum of 2 quarters · filed 2017-10-30 | $0.00 derived: sum of 3 quarters · filed 2017-10-30 | $0.00 10-Q · filed 2017-10-30 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31 | $0.00 derived: sum of 2 quarters · filed 2016-10-31 | $0.00 10-Q · filed 2016-10-31 | |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | $0.00 10-Q · filed 2016-08-01 | ||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-03 | |||
| 2015-12-31 | $0.00 10-Q · filed 2016-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |